Venter Reveals Sequels to Sequencing

In a low-key yet confident manner, J. Craig Venter addressed a host of issues ranging from proteomics to religion at a July 20 media forum in New York sponsored by Syracuse University. J. Craig Venter The president and chief scientific officer of Celera Genomics Group, of Rockville, Md., however, declined to comment on a rumor that he is one of five people whose complete genomes are being sequenced by his company, a unit of Norwalk, Conn.-based PE Corp. And he refused to predict the final

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

In a low-key yet confident manner, J. Craig Venter addressed a host of issues ranging from proteomics to religion at a July 20 media forum in New York sponsored by Syracuse University.


J. Craig Venter
The president and chief scientific officer of Celera Genomics Group, of Rockville, Md., however, declined to comment on a rumor that he is one of five people whose complete genomes are being sequenced by his company, a unit of Norwalk, Conn.-based PE Corp. And he refused to predict the final tally of human genes due later this year, suggesting that some biotech companies might be inflating the number "because they sell [the genes] as commodities."

Often without distinguishing between Celera and PE Corp., Venter said his firm is heavily committed to proteomics, the study of proteins encoded by the genome, and to cancer research. He boasted that the proteomics effort will benefit from new mass ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Douglas Steinberg

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio